Latest Breaking News On - Diabetic retinopathy severity score - Page 1 : comparemela.com

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) - Rezolute (NASDAQ:RZLT)

Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual

Tirtht-patel
Christen-baglaneas
Araj-agrawal
Arshad-khanani
Quan-dong-nguyen
Stanford-university-school-of-medicine
Head-of-ophthalmological-clinical-development-at-rezolute
Rezolute-inc
Securities-exchange
Reno-school-of-medicine
Byers-eye-institute

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

Met primary study endpoints: good safety profile and reduction in central subfield thickness First oral therapy to demonstrate reduction in macular edema; supports potential for early disease.

Christen-baglaneas
Quan-dong-nguyen
Araj-agrawal
Arshad-khanani
Tirtht-patel
Nasdaq
Reno-school-of-medicine
Securities-exchange
University-of-nevada
Rezolute-inc
Stanford-university-school-of-medicine

Rezolute Inc. (RZLT) Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402

Rezolute Inc. (RZLT) Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Araj-agrawal
Quan-dong-nguyen
Arshad-khanani
Christen-baglaneas
Tirtht-patel
Nasdaq
Stanford-university-school-of-medicine
Byers-eye-institute
University-of-nevada
Securities-exchange
Rezolute-inc

High-Dose Aflibercept Extended Dosing Reduces Diabetic Macular Edema Treatment Burden

High-Dose Aflibercept Extended Dosing Reduces Diabetic Macular Edema Treatment Burden
endocrinologyadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from endocrinologyadvisor.com Daily Mail and Mail on Sunday newspapers.

Diabetic-retinopathy-severity-score

Diana V. Do, MD: Therapeutic Benefit of Aflibercept 8 mg for DME in PHOTON Trial

At ARVO 2023, Do discusses the benefit of aflibercept 8 mg for DME in the phase 2/3 PHOTON trial, demonstrating non-inferiority in BCVA vs aflibercept 2 mg and no new safety concerns.

New-orleans
Louisiana
United-states
Byers-eye-institute
Association-for-research
Stanford-university-dianav-do
Stanford-university-school
Stanford-university
Ophthalmology-annual-meeting
During-weeks
Diabetic-retinopathy-severity-score